Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT02142205
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BIOLOGICAL:
BG00002
Sponsor
Biogen